EYPT
Live chart
What they do
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib.
For information only · Important disclosures
Grades vs sector
No sector grades for EYPT yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.68 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-2.20 vs trailing $-3.75. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 2/9 · last two fiscal years
Altman Z-score -11.3 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $31.4M | $-232.0M | $-243.4M |
| 2024 | $43.3M | $-130.9M | $-130.3M |
| 2023 | $46.0M | $-70.8M | $-1.6M |
| 2022 | $41.4M | $-102.3M | $-67.2M |
| 2021 | $36.9M | $-58.4M | $-50.3M |
| 2020 | $34.4M | $-45.4M | $-14.8M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -8.8%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | -0.96 | -1.09 | -13.9% |
| 2026-05-06 | -0.81 | -0.99 | -22.5% |
| 2026-03-04 | -0.75 | -0.81 | -8.0% |
| 2025-11-05 | -0.77 | -0.85 | -10.2% |
| 2025-08-06 | -0.80 | -0.85 | -6.0% |
| 2025-05-07 | -0.69 | -0.65 | +5.8% |
| 2025-03-05 | -0.48 | -0.64 | -34.3% |
| 2024-11-07 | -0.54 | -0.54 | -0.2% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $507.0K | -90.5% |
| 2026-03-31 | $696.0K | – |
| 2025-12-31 | $620.0K | – |
| 2025-09-30 | $966.0K | – |
| 2025-06-30 | $5.3M | – |
Rating changes
Third-party analyst actions, not Coteau's views. All rating changes
Insider trades
$52.3K
–
Stats refreshed 2026-10-21 01:32:02 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Beta 0.9 · Oct 21, 2026